Systemic adjuvant chemotherapy for soft tissue sarcomas.
Adjuvant chemotherapy for soft tissue sarcoma remains investigational. Continued study of multidisciplinary treatment programs in high-grade sarcomas in formal clinical trials remains a priority. The National Cancer Institute is currently conducting a randomized trial of postoperative adjuvant doxorubicin and ifosfamide as compared with observation in high-grade sarcoma. The completion and outcome of this trial will contribute to this ongoing debate. Finally, a better understanding of the biology of soft tissue sarcoma that determines subsequent clinical course may serve as a foundation for further investigation.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012509:Sarcoma / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D015996:Survival Rate
D000970:Antineoplastic Agents